Home|Journals|Articles by Year|Audio Abstracts
 

Review Article



Phytomolecules against inflammation and fibrosis in immunoglobulin A nephropathy

Rajiv Jash, Kousik Maparu, Sanket Seksaria, Sujan Banerjee, D. S. N. B. K. Prasanth, Himangshu Sekhar Maji.




Abstract

Out of diseases affecting kidney functions in humans, immunoglobulin A (IgA) nephropathy is the most common. Available treatments are mainly targeted to reduce proteinuria and creatinine levels and corticosteroids are the mainstay therapy to delay the end-stage renal disease (ESRD). However, corticosteroids are associated with dire adverse effects in 55% of the patients receiving the treatment consisting of metabolic disorders, osteoporosis, and others which drive the idea for the search for anti-inflammatory drugs which alleviate inflammation and fibrosis in the kidneys of the patients resulting in either cure or at least delay the ESRD. Phytomolecules have long been associated with the effective treatment of various disorders since ages. This study focuses on identifying the immunomodulatory pure molecules isolated from plants which can be studied for their effect in alleviating IgA nephropathy. All the phytomolecules mentioned in this study have inflammation-reducing properties as is evident from many studies mentioned here and IgA nephropathy, being an autoimmune disease, can be a good target of these phytomolecules. Various pathological pathways of IgA nephropathy can be targeted with these phytomolecules and this study is an effort to find out the rationale behind the choice of the molecules based on their ability to target the effector molecules of those pathological pathways.

Key words: Immunomodulator , Phytomolecules , End stage renal diseases, Immunoglobulin A nephropathy ,etc.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.